

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: **Bin Wang et al.**

Serial No.: **10/590,040**

Group Art Unit: **1656**

Filing Date: **January 31, 2005**

Examiner: **Not yet assigned.**

For: **T CELL IMMUNE RESPONSE INHIBITOR**

VIA EFS WEB

DATE SENT: June 22, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.
- ☐ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
 - ☐ the Statement under 37 C.F.R. § 1.97(e) (see “Statement” below);
 - or**
 - ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
 - ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see “Statement” below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see “Statement,” and “Fees” below).
- ☒ Copies of the references listed on the attached PTO Form SB/08b, formerly known as PTO Form 1449 are enclosed.

EXCEPT THAT:

- ☒ In view of the voluminous nature of references **AA, AB, and AC**, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- ☒ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Fees

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 50-0436 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ The Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account 50-0436.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,

/Mark DeLuca, Reg. No. 33,229/
Mark DeLuca
Registration No. 33,229

Dated: June 22, 2007

PEPPER HAMILTON LLP
500 Grant Street
One Mellon Bank Center, 50th Floor
Pittsburgh, PA 15219-2502

(610) 640-7855 - Telephone
(412) 281-0717 - Facsimile

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

| | |
|------------------------|------------------------------|
| Application Number | 10/590,040 |
| Filing Date | Intl Filing Date: 01/31/2005 |
| First Named Inventor | Bin Wang |
| Art Unit | Not assigned |
| Examiner Name | Not assigned |
| Attorney Docket Number | AM102431/WANG0002-100 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | *AA | Samabrook, et al., "Molecular Cloning", Cold Spring Harbor Press, N.Y. 2 nd edition, 1998. | |
| | *AB | Li, C., et al., editors, "Experimental Technologies in Biochemistry and Molecular Biology, Zhejiang University Press. | |
| | *AC | Doonan, "Protein Purification Protocols", Humana Press, N.J., 1996. | |
| | AD | Reiner, S.L., et al., "Constructing polycompetitor cDNA's for quantitative PCR", <i>Journal of Immunological Methods</i> , 165: p. 37-46, 1993. | |
| | AE | Jin, H., et al., "Effect of Chemical Adjuvants on DNA Vaccination", <i>Vaccine</i> , 22, p. 2925-2935, 2004. | |
| | AF | Li, W., et al., "Combined immunization of DNA vaccine and replication defective recombination adenovirus bearing rabies glycoprotein gene induces immune response against rabies virus", <i>Chin J. Microbiol Immunol.</i> , 22:403-406, 2002. (with English Abstract). | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
SignatureDate
Considered¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.